Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1923 - Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Cervical Cancer

Presenters

Linda Mileshkin

Citation

Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250

Authors

L.R. Mileshkin1, E. Barnes2, K.N. Moore3, V. Gebski2, M. King4, K. Narayan5, I.K. Kolodziej2, K. Sjoquist2, A. Fyles6, W. Small7, D. Gaffney8, M. Quinn9, J. Andrews10, S. Thompson3, W. Huh11, M. Carlson12, P.A. Disilvestro13, D. Rischin1, M.R. Stockler14, B.J. Monk15

Author affiliations

  • 1 Department Of Medical Oncology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 2 Nhmrc Clinical Trials Centre, University of Sydney, Sydney/AU
  • 3 Stephenson Cancer Centre, University of Oaklahoma Health Sciences Center, Oaklahoma/US
  • 4 Faculty Of Science, School Of Psychology, Quality Of Life Office, University of Sydney, Sydney/AU
  • 5 Department Of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne/AU
  • 6 Department Of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto/CA
  • 7 Department Of Radiation Oncology, Stritch School of Medicine, Loyala University Chicago Director, Cardinal Bernardin Cancer Center, Chicago/US
  • 8 Department Of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City/US
  • 9 Department Of Surgery, Peter MacCallum Cancer Centre, Melbourne/AU
  • 10 Clinical Trials, Australia New Zealand Gynaecological Oncology Group, Sydney/AU
  • 11 Department Of Obstetrics And Gynecology, University Of Alabama at Birmingham, Birmingham/US
  • 12 Department Of Obstetrics And Gynecology, University of Texas Southwestern Medical Center, Dallas/US
  • 13 Department Of Obstetrics And Gynecology, Women and Infants Rhode Island, Providence/US
  • 14 Nhmrc Clinical Trials Centre, University of Sydney, 2050 - Sydney/AU
  • 15 Division Of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospitla, Phoenix/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1923

Background

OUTBACK is testing the addition of 4 cycles of adjuvant carboplatin/paclitaxel chemotherapy (chemo) after definitive chemoradiation in locally advanced cervix cancer. We aimed to determine characteristics associated with not starting randomly assigned adjuvant chemo.

Methods

We assessed associations between not starting assigned adjuvant chemo and baseline characteristics of: age; race; country; smoking status; ECOG; BMI; FIGO stage; node involvement; and participants’ self-rated physical, role, emotional, cognitive, social functional status, and financial difficulties (by EORTC QLQ-C30). We also assessed for associations with completion of chemoradiation and grade 3-4 toxicities during chemoradiation. Odds ratios (OR), p-values, and 95% confidence intervals (CI) were calculated with univariable and multivariable logistic regression analyses.

Results

Adjuvant chemo was not started in 105 of 463 (23%) women randomly assigned to receive it. Predictors of not starting adjuvant chemo with a p-value of < 0.05 in univariable analyses, and their effects in multivariable analysis are shown in the table. The odds of not starting chemo were approximately doubled in non-Caucasian women, and those aged >/= 60, even after accounting for other factors.

Conclusions

Adjuvant chemo was less likely to be started in non-Caucasian women, those aged >/= 60, and those with poor self-rated physical function. Further research is required to understand the causes, implications, and methods for mitigating these disparities.

Clinical trial identification

ACTRN12610000732088.

Editorial acknowledgement

Legal entity responsible for the study

University of Sydney.

Funding

National Health and Medical Research Council. In addition, Hospira provided paclitaxel treatment for Australian and New Zealand patients in the study.

Disclosure

L. Mileshkin: Research grant / Funding (self), Provided supply of Paclitaxel for trial patients in Australia and New Zealand: Hospira; Travel / Accommodation / Expenses: Beigene; Travel / Accommodation / Expenses: Roche. K.N. Moore: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution): Immunogen; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy: Aravive; Advisory / Consultancy, Research grant / Funding (institution): OncoMed; Advisory / Consultancy: Samumed; Advisory / Consultancy: Eisai; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy: Cue; Research grant / Funding (self): Lilly; Research grant / Funding (self): PTC Therapeutics; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Agenus. K. Sjoquist: Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Servier; Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Ipsen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Bionomics; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Tilray. W. Small: Honoraria (self), Travel / Accommodation / Expenses: Zeiss; Advisory / Consultancy: Merck. S. Thompson: Honoraria (self): Mevion Medical Systems. W. Huh: Honoraria (self): Antiva; Advisory / Consultancy: Inovio. P.A. Disilvestro: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Immunogen; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Syros; Research grant / Funding (institution): Janssen. D. Rischin: Advisory / Consultancy, Research grant / Funding (institution), Uncompensated: MSD; Advisory / Consultancy, Research grant / Funding (institution), Uncompensated: Regeneron; Advisory / Consultancy, Research grant / Funding (institution), Uncompensated: GSK; Advisory / Consultancy, Research grant / Funding (institution), Uncompensated: BMS; Research grant / Funding (institution): Roche. M.R. Stockler: Research grant / Funding (institution): Astellas; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Bionomics; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Tilray. B.J. Monk: Advisory / Consultancy: AbbVie; Advisory / Consultancy: Advaxis; Advisory / Consultancy: Agenus; Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: ChemoCare; Advisory / Consultancy: ChemoID; Honoraria (self), Advisory / Consultancy: Clovis; Advisory / Consultancy: Conjupro; Advisory / Consultancy: Esaias; Advisory / Consultancy: Geistlich; Advisory / Consultancy: Genmab; Advisory / Consultancy: Immunogen; Advisory / Consultancy: Immunomedics; Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy: Janssen/Johnson & Johnson; Advisory / Consultancy: Merck; Advisory / Consultancy: Myriad; Honoraria (self), Advisory / Consultancy: Roche/Genentech; Honoraria (self), Advisory / Consultancy: Tesaro. All other authors have declared no conflicts of interest.Table: 1052P

CharacteristicValueAdjuvant chemo not started/ assigned: N (%)Univariable OR (95% CI)Univariable p-valueMultivariable OR (95% CI)Multivariable p-value
Age>/= 60 < 6024/70 (34%) 81 / 393 (21%)2.01 (1.2-3.5)0.012.30 (1.10-4.81)0.026
RaceOther White/Caucasian43/127 (34%) 62/336 (18%)2.26 (1.4–3.6)0.00052.11 (1.13-3.96)0.019
Nodes involvedYes No/unknown42/225 (19%) 63/238 (26%)0.64 (0.4–0.99)0.0460.75 (0.42-1.35)0.34
QLQ-C30 Physical FunctionWorst 33.37% Best 66.67%5/11 (45%) 59/310 (19%)3.55 (1.05–12.0)0.043.66 (1.03-13)0.045
ChemoradiationNot completed Completed46/114 (40%) 59/349 (17%)3.33 (2.01–5.3)<0.00013.21 (1.75-5.88)0.0002

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.